To demonstrate the effectiveness of lorazepam in treating catatonia and psychosis in a specific case of a Parkinson's disease patient with acromegaly.
Key Findings:
Lorazepam treatment led to complete resolution of catatonia and psychotic symptoms within six days.
The patient had a pituitary macroadenoma confirmed by MRI, contributing to her acromegaly.
Neuropsychiatric symptoms were exacerbated by the abrupt discontinuation of her medications.
Interpretation:
This case underscores the potential for lorazepam to effectively manage complex neuropsychiatric symptoms in patients with Parkinson's disease and comorbid conditions like acromegaly, highlighting the need for further research in this area.
Limitations:
The findings are based on a single case study, limiting generalizability to broader populations.
Long-term effects and safety of lorazepam in this context remain unclear, necessitating further investigation.
Conclusion:
Lorazepam can be an effective treatment for catatonia and psychosis in Parkinson's disease patients, particularly when complicated by other conditions such as acromegaly.
Baptist Health Foundation announced that it has received a $2 million donation from Anthony and Joyce Esernia to establish a new endowed chair at Baptist Health Miami Neuroscience Institute.
